. 2021 May 28;10(6):866. doi: 10.3390/antiox10060866

Table 1.

Changes in organ damage markers in serum (S)/plasma (P) and urine (U).

	Unit	Trial	Pre	Post	1h	2h	Trial	Time	Interaction
BUN-S	mg/dL			**			0.907	<0.001	0.902
		REH	18.88 ± 1.05	17.76 ± 1.12	19.80 ± 1.12	18.90 ± 1.16
		CON	19.02 ± 1.23	17.67 ± 1.12	20.05 ± 1.47	19.13 ± 1.36
Creatinine-S	mg/dL			**	**		0.429	<0.001	0.105
		REH	0.92 ± 0.03	0.84 ± 0.03	0.98 ± 0.03	0.92 ± 0.03
		CON	0.95 ± 0.04	0.88 ± 0.03	0.98 ± 0.03	0.93 ±0.04
Cystatin C-P	mg/mL				***		0.232	<0.001	0.326
		REH	0.74 ± 0.01	0.72 ± 0.01	0.80 ± 0.01	0.76 ± 0.02
		CON	0.74 ± 0.01	0.71 ± 0.02	0.77 ± 0.02	0.73 ± 0.02
Urine Protein-U	µg/min					**	0.528	0.001	0.183
		REH	41.08 ±10.48			73.23 ± 6.93
		CON	26.31 ± 5.84			75.10 ± 8.93
NAG-U	mU/min					**	0.930	0.001	0.624
		REH	29.88 ± 7.05			54.77 ± 6.13
		CON	26.52 ± 7.26			56.82 ± 6.68
Alubmin-U	mU/min					***	0.609	<0.001	0.469
		REH	43.82 ± 11.29			338.26 ± 67.74
		CON	47.80 ± 12.31			386.24 ± 74.32
Endotoxin-P	IU/mL	REH	ND	ND	ND	ND
Endotoxin-P	IU/mL	CON	ND	ND	ND	ND

Values are presented as mean ± SE. ** p < 0.01, *** p < 0.001 vs. Pre. BUN, blood urea nitrogen; NAG, N-acetyl-β-d-glucosaminidase; ND, not detected; REH, rehydrate trial; CON, control trial.